DexCom Quarterly Cash Flow Statement
NASDAQ: DXCMHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
DexCom free cash flow
In the quarter ended Jun 30, 2026, DexCom generated $269.2 million of operating cash flow and spent $84.7 million on capital expenditures. That left free cash flow of $184.5 million, a free-cash-flow margin of 14.1% of revenue. Free cash flow was down 11.7% from the prior year's $208.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
DexCom cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 249.10M | 199.50M | 267.30M | 283.80M | 179.80M | 105.40M | 151.70M | 134.60M | 143.50M | 146.40M | 256.30M | 120.70M |
| Net Income growth (YoY) | +38.54% | +89.28% | +76.20% | +110.85% | +25.30% | -28.01% | -40.81% | +11.52% | +23.81% | +201.23% | +179.19% | +19.27% |
| Depreciation & Amortization | 68.20M | 67.10M | 65.20M | 63.60M | 63.00M | 60.00M | 57.80M | 55.30M | 52.10M | 52.50M | 52.50M | 48.20M |
| Stock-Based Compensation | 39.00M | 43.30M | 35.00M | 45.10M | 45.30M | 34.20M | 43.30M | 43.40M | 44.70M | 39.00M | 36.90M | 39.00M |
| Change in Working Capital | -114.70M | 255.50M | -141.00M | 199.50M | 8.90M | -800.00K | 13.30M | 23.90M | 67.60M | 78.50M | -270.10M | 121.70M |
| Operating Cash Flow | 269.20M | 525.60M | 294.00M | 659.90M | 303.00M | 183.80M | 301.40M | 199.50M | 279.40M | 209.20M | 133.60M | 269.20M |
| Capital Expenditures | -84.70M | -76.60M | -101.90M | -80.50M | -94.10M | -87.00M | -124.60M | -111.20M | -66.10M | -56.90M | -52.50M | -50.40M |
| Investing Cash Flow | 329.80M | -298.50M | 306.60M | 192.80M | -63.60M | 100.20M | -303.70M | 210.30M | -188.90M | 74.80M | 414.90M | -179.50M |
| Share Repurchases | — | — | -312.80M | -187.20M | — | — | 0 | -750.00M | — | — | -500.00M | 0 |
| Financing Cash Flow | -607.30M | -25.00M | -1.52B | -175.00M | -1.70M | 12.50M | -1.60M | -736.50M | -1.40M | 4.70M | -631.90M | -637.40M |
| Net Change in Cash | -13.20M | 199.30M | -917.80M | 676.60M | 254.20M | 298.80M | -15.10M | -318.10M | 88.10M | 284.90M | -77.30M | -551.20M |
| Free Cash Flow | 184.50M | 449.00M | 192.10M | 579.40M | 208.90M | 96.80M | 176.80M | 88.30M | 213.30M | 152.30M | 81.10M | 218.80M |
This table shows 12 quarterly periods of DexCom's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DXCM's reporting calendar. What is a cash flow statement?